Bard (C.R.) Inc (BCR) Earnings Report: Q3 2015 Conference Call … · 2015-10-23 · Sales in...
Transcript of Bard (C.R.) Inc (BCR) Earnings Report: Q3 2015 Conference Call … · 2015-10-23 · Sales in...
CompanyName:CRBardIncCompanyTicker:BCRSector:HealthCareIndustry:HealthServices
EventDescription:Q32015EarningsCallMarketCapasofEventDate:14.07BPriceasofEventDate:178.44
©2014TheStreet,Inc.Al l R ightsReserved Page1of22
Bard(C.R.)Inc(BCR)EarningsReport:Q32015ConferenceCallTranscriptThefollowingBard(C.R.)IncconferencecalltookplaceonOctober22,2015,05:00PMET.Thisisatranscriptofthatearningscall:
CompanyPart icipants
TimothyRing;C.R.BardInc.;Chairman&CEOJohnWeiland;C.R.BardInc.;President&COOJohnDeFord;C.R.BardInc.;SVPScienceTechnologyandClinicalAffairsChristopherHolland;C.R.BardInc.;SVP&CFO
OtherPart icipants
BobHopkins;BofAMerrillLynch;AnalystMikeWeinstein;JPMorgan;AnalystBrooksWest;PiperJaffray&Co.;AnalystDavidRoman;GoldmanSachs;AnalystDavidLewis;MorganStanley;AnalystDavidTurkaly;JMPSecurities;AnalystKristenStewart;DeutscheBank;AnalystNeilChatterji;CowenandCompany;AnalystMattTaylor;BarclaysCapital;AnalystAnthonyPetrone;JefferiesLLC;Analyst
MANAGEMENTDISCUSSIONSECTION
Operator :
WelcometotheC.R.Bard,Inc.thirdquarter2015earningsresultsconferencecall.
(OperatorInstructions)
Asareminder,thisconferencecallisbeingrecordedandwillbeavailableforfutureondemandreplaythroughtheBardwebsite.
Today'spresentationwillbehostedbyTimothyM.Ring,ChairmanandChiefExecutiveOfficer,alongwithJohnH.Weiland,PresidentandChiefOperatingOfficer;ChristopherS.Holland,SeniorVicePresidentandChiefFinancialOfficer;andJohnA.DeFord,SeniorVicePresident,Science,TechnologyandClinicalAffairs.AlsoinattendancetodayisToddW.Garner,VicePresident,InvestorRelations.
Today'sBard'sManagementwilldiscusssomeforward-lookingstatements,theaccuracyofwhicharenecessarilysubjecttorisksanduncertainties.Pleaserefertothecautionarystatementsregardingforward-lookinginformationinBard'sJune30,2015,Form10-Q,andtheinformationunderthecaptionRiskFactorsinBard's201410K,includingdisclosureofthefactorsthatcouldcauseactualresultstodiffermateriallyfromthoseexpressedorimplied.
Duringthecallreferenceswillbemadetocertainnon-GAAPmeasureswhichManagementbelievesprovideanadditionalandmeaningfulassessmentofthecoreoperatingperformanceoftheCompany
CompanyName:CRBardIncCompanyTicker:BCRSector:HealthCareIndustry:HealthServices
EventDescription:Q32015EarningsCallMarketCapasofEventDate:14.07BPriceasofEventDate:178.44
©2014TheStreet,Inc.Al l R ightsReserved Page2of22
anditsindividualproductfranchises.Reconciliationsofnon-GAAPmeasurestothemostcomparableGAAPmeasuresareprovidedinBard'searningsPressReleaseandontheCompany'swebsitesatwww.crbard.com.
AllinformationthatisnothistoricalisgivenonlyasofOctober22,2015,andtheCompanyundertakesnoresponsibilitytoupdateanyinformationunlessotherwisenoted.Allcomparisonaretotheprior-yearperiod.
AtthistimeI'llturnthecallovertoMr.TimothyRing.Pleasegoahead.
T imothyRing (Chairman&CEO):
Thankyou.I'dliketowelcomeeveryonetoBard'sthirdquarter2015earningscallandthankallofyoufortakingthetimetojoinwithustoday.Weexpectthepresentationportionofthecalltolastabout30minutesandthetotalcalltolastaboutanhour.
Theagendatodaywillbeasfollows.I'llbeginwithanoverviewoftheresultsforthequarter.JohnWeiland,ourPresidentandCOO,willreviewthirdquarterproductlinerevenue.JohnDeFord,ourSeniorVP,Science,TechnologyandClinicalAffairswillgiveyouanupdateonourproductdevelopmentpipeline,andChrisHolland,ourSeniorVPandCFO,willreviewthethirdquarterincomestatement,balancesheet,aswellasourexpectationsforthefourthquarterandthen,finally,we'llclosewithQ&A.
Thirdquarter2015netsalestotaled$865.7million,that'sup4%overQ3oflastyearonanas-reportedbasisandup8%onaconstantcurrencybasis.Thecurrencyimpactforthequarterversusthesamequarterlastyearwasunfavorableabout370basispoints.
ExcludingtheGoreroyaltyof$38.4millionandsalesrelatedtorecentacquisitionsanddivestitures,ourorganicgrowthratewasapproximately8.3%forthequarter.That'saboveourexpectations.TheUSsalesoftheLutonixdrug-coatedballooncontributedalittlelessthan300basispointsofgrowthinQ3.
Netlossforthequarterof2015was$86millionanddilutedlosspersharewas$1.16.ExcludingtheseitemsthataffectedthecomparabilityofresultsbetweenperiodswhichChriswillcoverlater,thirdquarter2015netincomewas$154.5millionanddilutedearningspershare,whichexcludesamortizationofintangibles,were$2.28,that'sup4%and6%respectively.
Lookingatrevenuegrowthgeographicallycomparedtothesamequarterlastyear,thirdquarternetsalesintheUSwereup7%.Internationally,wegrew10%onaconstantcurrencybasiswithEuropegrowing7%,Japandeclining1%,andourotherinternationalbusinessesgrowing18%thisquarter.StrongquarterinEuropewasdrivenbyendovascularradiologyinPICCsandtheslightdeclineinJapanwasduetoinventoryfluctuationsatourjointventure.
Youmayhavenoticedafewweeksagoweannouncedtheacquisitionoftheremaining[50%]ownershipofourJapanesejointventure.Weexpectthistransactiontobecompletedinthecomingweeks.Whileitcomeswithsomenear-termdilutiondrivenbyexchange,webelievethisisstrategicallyimportantforus.
IncreasedinvestmentfrommarketdevelopmentinclinicaltrialsinJapanwasdifficultwiththestructureofthejointventurewhenyoucombinethatwithforeignexchangepressure,sowedecidedthiswasatimelyopportunitytotakefullownershipandadvanceourproductleadershipstrategyintheworld'sthirdlargesthealthcaremarket.
Ouremergingmarketsbusinesscontinuestogrowinthehealthydoubledigitsfollowingoursignificantinvestmentsthereoverthelastcoupleofyears,soaswelookatouroverallresultsforthequarter,andthefirstninemonthsof2015,wesaidatthebeginningoftheyearthatitwasanimportantyearof
CompanyName:CRBardIncCompanyTicker:BCRSector:HealthCareIndustry:HealthServices
EventDescription:Q32015EarningsCallMarketCapasofEventDate:14.07BPriceasofEventDate:178.44
©2014TheStreet,Inc.Al l R ightsReserved Page3of22
executionforusandsofar,we'repleasedwiththeresults.Asweprojectedattheannouncementofourstrategicinvestmentplannearlythreeyearsagonow,wearebackatthetopendofthesectorfromarevenuegrowthperspectiveandweremainconvincedthatabovemarketrevenuegrowthisakeytoapremiummultiple.
Weremainfocusedonmakinginvestmentsinareasoffastergrowthinaprofitablemannertoenhanceshareholdervalueoverthelongterm.Sowiththat,letmeturnyouovertoJohnWeilandforareviewofourproductlinerevenue.
JohnWeiland (President&COO):
Goodafternoon,everyone.BeforeIstart,letmepointoutthatIwillbegivingallpercentagegrowthdataincomparisontotheprior-yearperiodonaconstantcurrencybasisunlessotherwisenoted.
Solet'sbeginwithvascular.Growthinthiscategorywas13%forthequarteror8%asreportedwithtotalnetsalesof$250.5million.ExcludingtheGoreroyalty,andthedivestedEPsales,totalvascularsalesgrew16%globallywiththeUnitedStatesbusinessup18%andtheinternationalbusinessgrowing14%inthequarter.
Salesinoursurgicalgraftcategorywereup4%inQ3.ExcludingtheGoreroyalty,ourendovascularbusinessincreased18%inthethirdquarter.Withinendovascular,ourbiopsyproductshadanotherstrongquarterwith14%growth,withniceperformanceintheUnitedStatesandevenbetterperformanceoutsideoftheUnitedStates.
SalesinourperipheralPTAlineincreased48%,drivenbyglobalsalesofourLutonixdrug-coatedballoon.WeareverypleasedwiththeperformanceofthisimportantproductwhichanniversarieditsFDAapprovalandtheUSlaunchonOctober10.Ithasbeenagoodfirst12monthsintheUnitedStatesandwe'repleasedwiththeresultsfromourrealworldregistrystudy.JohnDeFordwilltellyoumoreaboutthisinafewminutes.
Asweseektoexpandtheindicationsandreachofthiscompellingtechnologyplatform,weexpecttoseelong-termglobalgrowthfromLutonix.Ourstentbusinessdeclined3%againthisquarter,consistentwithrecentexperience.Andfinally,netsalesinourvenacavafilterlinedeclined3%inQ3.
Solet'sgotourology.Totalnetsaleswere$212.3million,up5%versusQ3oflastyearonaconstantcurrencybasisand1%onanas-reportedbasis.TheUnitedStatesbusinessgrew5%whileinternationallygrew4%.Ourtargetedtemperaturemanagementproductsgrewinthehealthydoubledigitsagainthisquarter.
Ourbasicdrainagebusinesswasup6%globallyinQ3withtheUnitedStatesbusinessup7%.OurICFoleybusinesswasup3%globallyandup1%intheUnitedStates.WebelievethatFoleysthisquarterbenefitedfromsomedealerstockingbutwedon'tknowthepreciseimpact,sowewouldcautionagainstreadingtoomuchintotheseimprovedgrowthratesinasinglequarter.
Ourcontinencebusinessdecreased3%inthethirdquarter.Salesinurologicalspecialtiesgrew1%withourBrachiotherapybusinessdown1%.Andfinallyinthiscategory,standalonesalesofourstatlockcatheterstabilizationproductlinedeclined4%inQ3.
Nowlet'sgotooncology.Totalnetsalesinthiscategorywere$239.3million,anincreaseof8%onaconstantcurrencybasisand4%onanas-reportedbasisoverthethirdquarterlastyear.GeographicallynetsalesintheUnitedStateswereup5%andinternationalsaleswereup15%.Ourportbusinessdecreased1%thisquarterduetothepricereductionsintheUnitedStatesthatwetalkedaboutatthebeginningoftheyear.
CompanyName:CRBardIncCompanyTicker:BCRSector:HealthCareIndustry:HealthServices
EventDescription:Q32015EarningsCallMarketCapasofEventDate:14.07BPriceasofEventDate:178.44
©2014TheStreet,Inc.Al l R ightsReserved Page4of22
OurPICCrevenuewasup13%inthethirdquarter,includingstrongresultsintheUnitedStates,Europe,andemergingmarketsagainthisquarter.We'reverypleasedwiththeclinicaladoptionofouradvancedtechnologywhichhelpspatientsandcansavetimeandcostsforthehospital.
Despitethecompetitivenoiseonsinglefeatureshereandthere,webelievethatthequalityandperformanceofourbroadproductofferingiswhywecontinuetogrowfasterthanthemarket.Andasthecompetitiontriestocatchuptoourolderproducts,wecontinuetoadvancethetechnologyandsolveunmetneedsforourcustomersandourpatients.JohnDeFordwilltellyoumoreaboutthis.
Ourvascularaccessultrasoundproductlinewasup1%thisquarter.Thegrowthratesforthissystemcanbealittlelumpyaroundnewproductlaunchesandthat'swhatwe'reseeingduetodivision2launchintheprioryearanddependingSite-Rite8launchlaterthisyear.Andtocompleteoncology,ourdialysisaccessproductlinewasup12%overQ3oflastyear.
Solet'sconcludewithoursurgicalspecialtiesbusiness.Totalnetsalesinthiscategorywere$139.8million,up6%onaconstantcurrencybasisandup3%asreported.UnitedStatessaleswereup6%andinternationalsalesgrew4%thisquarter.
TwoyearsaftertheacquisitionoftheAristahemostatandthreeyearsaftertheacquisitionoftheprogelsealanttechnology,ourcombinedbiosurgicalproductportfoliocontinuestogrowdoubledigits.Oursofttissuerepairbusinessgrew7%inQ3,withoursyntheticventralherniarepairproductsgrowing6%,whileournaturaltissueproductsgrew14%,drivenbyournewXenMatrixAB,coatedporcinemesh.
Ourherniafixationbusinessgrew2%thisquarter,whichwasthefirstquarterinpositiveterritory,sincethesecondquarterof2011.Wearehopefulthatournewproductlaunchesherecanreversethetrendofdeclinesinrecentyears.Andclosingoutthesurgicalcategory,ourperformanceirrigationbusinesswasdown20%inQ3,aswetoldyouwediscontinuedsomeproductsearlierintheyear.
ThisconcludesourproductlinerevenuediscussionandnowI'llturnyouovertoJohnDeFord.
JohnDeFord (SVPScienceTechnologyandClinicalAffairs):
Thank,Johnandgoodafternoonormaybeit'seveningforeveryone.Thanksfortakingtimetojoinustoday.Forthesakeoftime,I'lljumprightintosomehighlightsstartingwithdrug-coatedballoons.
AbouttwoweeksagoatTCT,wereleasedfull12-monthresultsfromouralmost700patientglobalSFAandpoplitealregistry.Lesionlengthswereover100-millimeters.Abouthalfthepatientshadsignificantcalcificationandover30%ofthelesionstreatedwerechronictotalocclusions.Thestudyfoundover94%ofpatientswerefreefromTLRthroughthe12-monthfollow-upwithprimarypatencyinalmost90%ofpatients.
Interim24-monthresultsdemonstrated93%freedomfromTLR,andprimarypatencyinexcessof80%.WebelievethelearningsfromtheLevont2studyonkeystoasuccessfulprocedureareworkingtheirwayintorealworldpracticeandwe'reverypleasedwiththeresults.
Andourbelow-the-kneeIDEenrollmentcontinuesthoughrecruitmentremainsslowerthanplannedduetothecomplexnatureofthesepatientsandtheirdisease.We'reworkingwithFDAtofindwaystospeedupenrollmentandanalysisinthisimportantstudy.Atcurrentrecruitmentrates,wewilllikelycontinuetoenrollpatientsthroughmuchof2016,puttingPMAsubmissioninthesecondhalfof2017.
Ontheotherhand,ourAVaccessDCBIDEstudythatbeganenrollmentlastquarterisrecruitingveryquicklyandweanticipateenrollmentcouldbecompleteasearlyasQ1of2016,whichcouldputPMAsubmissionaheadofscheduleinthefirsthalfof2017.Thein-stentrestenosisIDEstudyisongoingandwe'recurrentlyplanningasecondhalf2016PMAsubmissionseekingthisexpandedindication.
CompanyName:CRBardIncCompanyTicker:BCRSector:HealthCareIndustry:HealthServices
EventDescription:Q32015EarningsCallMarketCapasofEventDate:14.07BPriceasofEventDate:178.44
©2014TheStreet,Inc.Al l R ightsReserved Page5of22
WehaveahostofotherDCBstudiesongoingorinstartuparoundtheworldandweplantobeginenrollmentinourLevontChinastudyinQ1of2016.Alsoinvascular,thelivestreamballoonexpandablecoveredstentIDEcompletedenrollmentinQ3.Thisclinicalstudyisevaluatingthetechnologyforthetreatmentofiliacarterydiseasewithaninemonthfollow-up.WeanticipatePMAsubmissioninthesecondhalfof2016.
OurCoverraNextGenerationstentgraft,designedforuseintheAVaccesscircuit,isplannedforlaunchinEuropethisquarterandwe'reworkingwithFDAtocommenceourUSIDEstudyinthefirsthalfof2016.OurnewdenovoVenusstentrecentlygainedtheCEmark.AswithCoverra,we'reworkingcloselywithFDAtoinitiateanIDEstudyseekingUSapprovalwithenrollmentplannedtobegininthefirsthalfofnextyear.
Nextmovingtourologyandhomecare,we'repleasedtoannouncethereleaseofthenewMagic3Goself-lubricatedcatheterforfemalepatients.Thisproductisdesignedforenhancedcomfortandease-of-useforpatientsthatoftenhavelimiteddexterity.WeplantorolloutthisproductselectivelyduringQ4aswerampmanufacturing.
WealsoanticipatethelaunchofourMagic3touchlesscatheterinearly2016.Bothoftheseproductsemployourlatestsilicontechnologydesignedtoenhancepatientuseandcomfort.We'vegotsomeotherimpactfulproductsinthisportfolioforlaunchlaterin2016,butI'llholdoffsharingthedetailsuntilwegetclosertothoselaunches.
Nowmovingtooncology,thenewSite-Rite8ultrasoundsystemwithintegrated3CGdiamondisrollingoutinEurope.TheSite-Rite8,withpinpointGTand3CGdiamondisontrackforUSlaunchinQ4asJohnalludedto.Webelievethecombinationofultrasound,needleguidanceandcathetertipconfirmationinanintegratedsystemwillprovideafull-featured,user-friendlyandintuitivesolutionforvascularcatheterplacement.
InPICCs,we'vesubmittedthe510KandawaitFDAclearancetolaunchanewandproprietarycatheterfamily.ThesePICCshavebeendesignedtoresistcommonchemicalsusedinchemotherapysolutionsaswellascleaninganddisinfectionagents.WhilethesesolutionsareknowntodegradestandardPICCmaterials,thisnewcathetercanmaintainthesamehighperformancestandardsavailableinourcurrentPICCs,evenafterlong-termexposure.
We'realsoexpandingourdevelopmenteffortstowardtechnologieswebelievecanfurtherreducetheriskofthrombosis.Whileweprefertokeepourdevelopmentplansconfidential,Iwillsaywehaveanewproductfamilyunderdevelopmentthat'sbasedonanewhigh-performancematerial.Weexpecttobeginlaunchingproductsusingthisnewmaterialinthebackhalfofnextyear.
Ourcurrentplansalsoanticipatecommencementofstudiestoprovidefurtherclinicalevidencetosupportthebenefitsofthesenewdesigns.Inconcertwiththeseefforts,we'vealsorecentlylaunchedatrainingprogramandsomeassociatedproductsdesignedtoreduceinfectionsandpromotethesafeandeffectiveuseofourPICCs.Withthischangeinnear-termfocus,we'vereducedthepriorityweplacedonouranti-microbialandthrombo-resistantcoatingtechnologies.Thedevelopmentsareongoing,butwedon'tbelievetheywillhaveamajorrevenuecontributioncomparedtotheseotheropportunities.
ForthedifficultstickIVcatheterpatients,weannouncedonthelastcalltheacquisitionoftheAccucathguidewire-assistedPIVproducts.We'vetakenthattechnologyintoourdevelopmentengineandanticipatethelaunchofanimprovedfamilyofAccucathproductsinthefirsthalfof2016.Theseproductsareanticipatedtolaunchalongsideourmidlinecatheter,thePowerglidePro,alsoplannedforlaunchinthatsametimeperiod.
WebelievethecombinationofourPICCs,thePowerglidemidlinefamilyandAccucathIVproductlinewill
CompanyName:CRBardIncCompanyTicker:BCRSector:HealthCareIndustry:HealthServices
EventDescription:Q32015EarningsCallMarketCapasofEventDate:14.07BPriceasofEventDate:178.44
©2014TheStreet,Inc.Al l R ightsReserved Page6of22
helpusbringimportantguidewire-assisteddevisestoabroadspectrumofpatientswithvascularaccessneeds.
Lastlyfortheacutehemodialysispatient,we'reexpandingourfamilyofcatheterswiththeexpectedlaunchofanewduallumenpower[Zemesis]catheterinQ1ofnextyear.Zemesisisdesignedforsuperiorflexibilityandkinkresistance,alongwithflowratesinexcessof400milsperminuteinasmall11Frenchcatheterconfiguration.
I'llclosemyportionofthediscussiontodaywithsurgery.JustafewweeksagowelaunchedournewPhasixSTresorbablesyntheticmesh.ThislaunchaddsanotherdifferentiatedproducttoourcomplexabdominalwallportfoliothatincludesXenMatrix,XenMatrixAB,andthePhasixmeshtechnology.
We'recontinuingoureffortstoexpandourproductofferingsbasedonthePhasixplatformandweexpecttobeginlaunchingthosenewproductsoverthenextseveralquarters.We'realsomakinggoodprogressonourdevelopmentofadditionalsizesofouroneofakindantibioticcoatedXenMatrixABfamilywithlaunchesexpectedthroughout2016andinto2017.
Inourbiosurgeryproductoffering,onourlastcallItoldyouwe'dfiledourPMAsupplementseekingapprovalofournewTri-dinevascularsealant,andwecontinuetoanticipateapprovalandlaunchinthebackhalfofnextyear.
AndfinallyinmeshfixationwerecentlylaunchedboththeOptifixspring-loadedresorbabletackdeviceandtheCapSurePermanentfixationproduct.We'reworkingtobuilduponthatmomentumthroughthelaunchoftwoadditionalfixationdevises,butduetothecompetitivenatureofthismarket,I'llholdbackthedetailsforalatercall.
Thanksforyourtimeandattentiontonight.LetmenowhandyouovertoChris.
ChristopherHolland (SVP&CFO):
Thankyou,John.Let'sstartwiththeitemsthataffectthecomparabilityofourresultsbetweenperiods.InQ3wehadacquisition-relateditemsof$2.5millionanda$14.6millionchargeforrestructuringandproductivityinitiatives.
Thisquarterwehavemadesignificantadditionalprogressinsettlementactivityrelatedtoourwomen'shealthproductliability.Drivenbythissettlementprogressandadditionalinformationlearnedfromit,aswellasrecentactivityinotherproductliabilitymatters,wetookanadditionalcombinedchargeof$241.1millionthisquarter.TheP&LimpactfortheseitemsisdetailedinthenotestothefinancialstatementsandthereconciliationaccompanyingourQ3earningsPressRelease.
Nowlet'sgothroughthestatementofincomeforthequarter.Grossprofitwas$529.4million,or61.2%ofsalesforQ3.Onanadjustedbasisgrossprofitwas$530.3million,or61.3%ofsales,alittlebetterthanweprojectedanddown120basispointsfromtheprioryear.Newamortizationofintangiblesrelatingtotransactionsclosedinthelast12monthswasabout50basispointsthisquarterandforeignexchangedroveapproximately30basispointsofheadwindforusinQ3.
Pricewasunfavorableby90basispointsontherevenuelineandapproximately30basispointsingrossprofitandourmixwasfavorablebyabout40basispointsthisquarter.Asweforecastedlastquarter,themanufacturingvariancesinourplantsfromyeartoyearcanbealittlelumpyandQ3isanexampleofthat.
InQ2,costsavingsdrove90basispointsofimprovement,butinQ3itwas50basispointsnegative.InQ4welookforQ4tolookmorelikeQ2withstrongfavorability.SoweexpectgrossprofitinQ4onanadjustedbasistobeameaningfulimprovementoverQ3andbacktotheQ42014levelormaybeevena
CompanyName:CRBardIncCompanyTicker:BCRSector:HealthCareIndustry:HealthServices
EventDescription:Q32015EarningsCallMarketCapasofEventDate:14.07BPriceasofEventDate:178.44
©2014TheStreet,Inc.Al l R ightsReserved Page7of22
littlebitbetter,whichwouldputusnearthehighendoftheoriginalguidancewegaveyouforgrossmarginsforthefullyear.Soitsbeenayearofsolidorganicimprovementforusonthegrossmarginline.
SG&Aexpenseswere$247.1millionforthequarter,or28.5%ofsales.Onanadjustedbasis,SG&Awasalso28.5%ofsales,down60basispointsfromQ3oflastyear.I'llremindyouwetypicallyseeanuptickinSG&AasapercentofsalesinQ4sequentially,butweexpecttostillseegoodleveragecomparedtotheprioryearandexpecttobewithinourfull-yearguidancefor2015.
R&Dexpenditurestotaled$65.2millionor7.5percentofsalesonareportedbasisforthethirdquarter,whichwasthesameonanadjustedbasis,down40basispointsfromtheprioryearandrightonourfull-yearguidance.Wefeelgoodaboutthelevelofinvestmentandinnovationandcontinuetodriveanactivenewproductpipelinetowardfasterrevenuegrowthopportunities,asyoucouldprobablytellfromJohnDeFord'supdate.
Interestexpensewas$11.2millionforthethirdquarter,nochangefromtheprioryear.Otherincomeandexpensewas$258.3millionofexpenseforthethirdquarterasreportedand$1.8millionofexpenseonanadjustedbasis.
Theeffectivetaxrateforthequarterwas24.9%,whichisthesamefortheninemonthsyear-to-datewherewearedown50basispointscomparedtotheprioryear,consistentwithouroriginalguidance.WedoexpecttherenewaloftheR&DtaxcreditbeforetheendoftheyearwhichwouldlowertherateinQ4.
Dilutedsharesonadjustedearningsfortheperiodwere$75.4millionandwerepurchased767,000sharesduringthethirdquarter.ThenetresultisadjustedcashEPSforQ3of$2.28abovetheguidancerangeweprovidedforthequarter,drivenbythehighersales.ThebalancesheetasofSeptember30reflectscash,restrictedcashandshort-terminvestmentsof$1.1billion,nochangefromJune30.
Forthequarter,accountsreceivabletodaysweredown1.6daysandinventorydaysweredownthreedays.CapitalExpenditurestotaled$21.7millionforthequarter.Ontheliabilityside,totaldebtwas$1.4billionasofSeptember30,nochangefromJune30.Debttototalcapattheendofthethirdquarterwasabout49%andtotalshareholderinvestmentwas$1.5billionatSeptember30.
Nowmovingtofinancialguidance.Atthebeginningofthisyear,weguidedorganicrevenuegrowthtobebetween4%and5%forthefullyearandwe'renowexpectingtobecloserto6.5%.ThatincludeslappingtheanniversaryoftheUSlaunchofLutonixinQ4of2014whichincludedsignificantadditionalstockingorders.
Excludingthoseinitialstockingordersfromlastyear,whichweestimaterepresentabout1percentofsalestothequarter,weprojectQ4organicsalesgrowthbetween5%and6%withabout300basispointsofheadwindfromFXandanadditional200basispointsofheadwindfromothersalesreductionsonareportedbasis.ThebiggestofthesereductionsrelatestothependingacquisitionoftheJapanesejointventure,whichwouldaddabout$40milliontooperatingrevenueonanannualbasis.However,thejointventureisholdinginventorywe'vealreadyrecordedassalestothem,soweexpecttohaveanegativeimpacttoreportedrevenueinQ4andQ1untilweworkthroughthatinventory.
Wealso,aswe'vediscussedinpriorcalls,expectthesalesofEPproductstoBostonScientifictodeclineinQ4asthey'venowstartedmanufacturingsomeofthoseproductlinesthemselves.Soweareprojectingreportedrevenuetobeflattodown1%inQ4eventhoughtheorganicmomentuminthebusinessisexpectedtoremainquitestrong.
NowtoupdateourexpectationsforadjustedcashEPS.FollowingourannouncementoftheacquisitionofourJapaneseJV,ourlatestforecastwas$8.95to$9.05forthefullyear.Todayweareraisingthat
CompanyName:CRBardIncCompanyTicker:BCRSector:HealthCareIndustry:HealthServices
EventDescription:Q32015EarningsCallMarketCapasofEventDate:14.07BPriceasofEventDate:178.44
©2014TheStreet,Inc.Al l R ightsReserved Page8of22
guidancetobebetween$9.03and$9.07.
Atthemidpointthisalsorepresentsa$0.05increasetoouroriginalfull-yearguidanceprovidedinJanuarydespiteabsorbingapproximately$0.15ofexpectedcombineddilutionfromacquisitionsandworseningFXduringtheyear.SpecifictoQ4,thismeansweexpectadjustedcashEPStobebetween$2.38and$2.42,whichincludesabout$0.06fromtherenewaloftheR&Dtaxcredit.
Thisperformancespeakstothestrengthofourexecutionin2015.We'vebeenabletoincreaseinvestmentsinthebusinesswiththeobjectiveofsustainingabove-marketrevenuegrowthwhileabsorbingdilutionalongthewayandyetwestillexpecttoincreasetheEPSdeliveredonthebottomlinein2015aboveourinitialexpectations.
Thankyouforyourattention.I'llnowturnyoubacktoTim.
T imothyRing (Chairman&CEO):
Thanks,Chris.Thatdoesconcludetheformalpartofthepresentation.I'llnowhandthecallouttothemoderatortofacilitatetheQ&Asession.Duetothenumberofinvestorsonthecall,I'daskthatyoulimityourselftoonequestionandonefollow-up.
QUESTIONS&ANSWERS
Operator :
Thankyouverymuch.And,ladiesandgentlemen,wewillnowbeginthequestion-and-answersession.
(OperatorInstructions)
ThefirstquestionwillcomefromBobHopkinswithBancofAmerica.
BobHopkins (Analyst-BofAMerrillLynch):
Thanks.Canyouhearmeokay?
T imothyRing (Chairman&CEO):
Yes,Bob.
BobHopkins (Analyst-BofAMerrillLynch):
Great,goodafternoon.Sotwothings.OneforChrisandoneforTim.First,Chris,IwasjustwonderingifyoucouldgooversomeofthethoughtsonQ4,especiallyastheyrelatetotheEPbusinessinJapan.Sothat5%to6%revenuegrowth,doesthatexcludethosetwothings?Andcanyoujustgointoalittlemoredetailonhowthosetwothingsimpacttheguidanceyou'vegivenontopandbottomline?
ChristopherHolland (SVP&CFO):
Sure,sowhatwe'resayingforQ4organic,excludingthestockingimpactfromlastyear'sQ4is5%to6%,soaboutapointupfromLutonixstockinglastyeargetsyouto4%to5%organic.There'sthenabout2%thatrelatesspecificallytothedeclineinBostonsalesexpectedinthequarterandtheimpactoflowersalesintoJapanasaresultofusexpectingtoclosetheacquisitioninacoupleofweekshere.
Sothecombinationofthoseandaflatcoreroyaltyreducedsalesby2%,soyougettheconstantcurrency,ifyouwill,Bobof2%to3%forthequarter.AndthentheFXimpact,aswesaid,isgoingtoreducesalesby3%,sothatthengetsustothenegative1%to0%onareportedbasis.
CompanyName:CRBardIncCompanyTicker:BCRSector:HealthCareIndustry:HealthServices
EventDescription:Q32015EarningsCallMarketCapasofEventDate:14.07BPriceasofEventDate:178.44
©2014TheStreet,Inc.Al l R ightsReserved Page9of22
BobHopkins (Analyst-BofAMerrillLynch):
Allright,I'msuretherewillbesomefollow-uponthatbutIwantedtoaskoneofTimformysecondquestion.So,Tim,couldyougiveusyoursenseastothebroaderutilizationenvironmentthatyousawinthequarter?Andifyouwouldn'tmindbreakingitoutbytheUSandthenseparatelyemergingmarkets.
AndIaskitthatwaybecauseitlookslikeyouguysareseeingreallygoodgrowthinemergingmarkets.SomeoftheorthopaedicplayerslikeJ&JandStrykerhavereportedaslowdowninimplantratesinBrazilandChinaandjustwantedtogetyour,again,youbroadercommentsonutilizationbrokendownUSandemergingmarkets.
T imothyRing (Chairman&CEO):
Again,Bob,Ihesitatetocalltrendsoutofaquarter-to-quarterkindofaswingjustbecausethere'ssomuchuncertaintygoingonallthetime,butIwouldhavetosaythatourutilizationwasprettystrong,orourvolumewasstrongeverywhere.Therewasn'tanyweakness,otherthankindoftheonewecitedinJapan,geographicallyinemergingmarketsremainsverystrongforus.
Wewatchandhearandreadwhateverybodyelsereportsandwekeeplookingforthat,bothintheprojectionswegetinfromthebusinessesandouractuals.Wejusthaven'tseenit.SoIwouldsaysimilartowhatwesawlastquarteroverall.
BobHopkins (Analyst-BofAMerrillLynch):
Allright,great,thankyou.
Operator :
Thankyou.ThenextquestioninqueuewillcomefromMikeWeinsteinwithJPMorgan.
MikeWeinstein (Analyst-JPMorgan):
Thanks.Chris,IthinkIneedyourhelp.I'mstillstrugglingalittlebitwiththefourthquarterguidanceaswell.Sofirstpartofitiswhy--asIunderstand,LutonixhadstockinginthefourthquarterbutLutonixrevenuesshouldyear-over-yearbeup.Whyareyoudescribingitas100basispointheadwind?
Andthensecond,justwanttomakesureIunderstandtheimpact,bothtoplineandonthegrossmargin,oftheJapanesejointventurebuy-ininthefourthquarter,thatalmost200basispointreductionyou'resayingiscomingfromJapan.WastherestockingofproductsintoJapanoverthelastcouplequartersthatwouldhavebenefitedthosequartersrelativetokindofunderlyingtrends?Thanks.
ChristopherHolland (SVP&CFO):
Sure,Mike.IthinkwhenwetalkaboutLutonix,andwetalkedaboutQ2andQ3withsalestoBoston,right,asBostonsteppedupsalesandwetalkedaboutstockinginQ2withBoston,wethinkwe'veactuallyseensomestockinginQ3aswell.
Weactuallylaunchedacoupleofadditionallengthsinthequarteraswell.SoIthinkcertainlyaswelookatQ4asitrelatestoBoston'sorderpattern,wewouldcertainlyexpecttoseeasequentialdeclineastheybegintonowworkthroughthatinitialinventory.Sothat'scertainlyimpactingtheoverallgrowthrateforLutonixaswelookatQ4.
We'reseeingcontinuedverystrongorganicgrowthinLutonix,relativetolastQ4,thoughwehadalargestockingorderinourownbusiness,right?Andsoit'sthatlappingofthataswellasthesequentialsalesintoBostonthatarejustdrivingsomeofthesequentialmovesforLutonix.
CompanyName:CRBardIncCompanyTicker:BCRSector:HealthCareIndustry:HealthServices
EventDescription:Q32015EarningsCallMarketCapasofEventDate:14.07BPriceasofEventDate:178.44
©2014TheStreet,Inc.Al l R ightsReserved Page10of22
MikeWeinstein (Analyst-JPMorgan):
Buthowareyoucomingupwiththat100basispoints,justsowecanunderstandwhatthatis?
ChristopherHolland (SVP&CFO):
Yes.That'sour--asweevaluatedlastyear'sQ4salesofLutonix,that'sourestimateofwhatthestockingcomponentofthosesaleswere.
MikeWeinstein (Analyst-JPMorgan):
Okay,soyou'rebasicallytakingoutthestocking,butyouaren'tgivingyourselfcreditfortheunderlyingsales?
T imothyRing (Chairman&CEO):
Yes,we'venotprojectedanumberforLutonixforQ4,Tim.TheanalysisthatChrisgave.
MikeWeinstein (Analyst-JPMorgan):
Okay,butyou'regivingyourselvesapenaltybutnotthebenefit?
ChristopherHolland (SVP&CFO):
Yes,butIthinktheothersequentialimpactissales--areexpectedsalesintoBoston.
MikeWeinstein (Analyst-JPMorgan):
Understood.Okay,I'msorry.AndthenjusttheJapanpiece,Chris?
ChristopherHolland (SVP&CFO):
Theonlyimpactthere--andit'sabout$11million,Mike.Andtheway--solastyear,wewould,intheordinarycourse,besellingproductintotheJV,astheyareobviouslythensellingout.Theymaintainlevelsofinventorythataresimilartousandsimilartothesector.Thesalesthatwemaketothem,onceweclosethetransaction,wewillnotrecorduntilthey'resoldoutthedoor.
Andsotheyaresittingoninventorytoday.Wehaven'tclosedthetransactionthatwe'vealreadyrecordedsalesforastheythensellthoseproductsoutthedoorinNovember-December,wecan'trecordthesaleagain.Intheordinarycourse,we'llcontinuetoshipproducttothem,whichiswhatwedidlastyear,butthere'sadelaynowasthatinventoryneedstogetsoldoncewehavefullownershipoftheJV.
MikeWeinstein (Analyst-JPMorgan):
Somyquestion,Chris,isthat--beforedistributorsusuallyboughttheyhaveanincentivetostockuponextraproduct.AndI'mmakingsurethattheJapanesedistributerwasn'tbuyinginexcessproducttohaveasmuchontheirshelvesbeforetheconversion.
ChristopherHolland (SVP&CFO):
No.Tobeveryclear,nothingabouttheirorderpatternslastyearandtheirorderpatternsthisyeararedifferentatall,soit'spurelythemechanismthatoncewehaveownership,right,wejusthavetowaitfortheinventorytoclearbeforewerecordadditionalsales.
MikeWeinstein (Analyst-JPMorgan):
Gotit.Veryclear.Thanks,guys.
CompanyName:CRBardIncCompanyTicker:BCRSector:HealthCareIndustry:HealthServices
EventDescription:Q32015EarningsCallMarketCapasofEventDate:14.07BPriceasofEventDate:178.44
©2014TheStreet,Inc.Al l R ightsReserved Page11of22
ChristopherHolland (SVP&CFO):
Sure.
Operator :
ThenextquestioninqueuewillcomefromBrooksWestwithPiperJaffrey.
BrooksWest (Analyst-PiperJaffray&Co.):
Hi,onemorejustonthatlasttopic.Chris,yousaid$11millionimpactfromJapaninQ4.Yousaidthere'sgoingtobealittlebitintoQ1.WhatistheimpactinQ1?
ChristopherHolland (SVP&CFO):
It'saboutthesameimpact.
BrooksWest (Analyst-PiperJaffray&Co.):
Okay.AndthenthelastpartofthatisjustsomedeclineinEPsalestoBostonScientific.Isthatasurprisethatthat'sdroppingofforwasthatpartoftheforecast?And,again,couldyouquantifythat?
ChristopherHolland (SVP&CFO):
Yes,sure.Actuallyifyougobacktoeachquarter,we'veactuallytalkedaboutitbothcomingintotheyearandtheneveryquarter,becauseactuallywhattheydidpriortothisquarter,weactuallywereseeinggrowthinsalestothemastheywereactuallybuildinginventoryinanticipationoftheshifttoself-manufacturing.
We'vetakenthosesalesoutoforganicgrowthobviouslytheentireyear.AndsowetalkedaboutQ4beingthefirstbigquarterwherewewouldseestep-downsbecausetheynowhaveactuallystoodupthemanufacturingplaninCostaRica.Sothatimpactinthequarterisroundnumbers,about$5million.SobetweenthatandJapan,you'retalkingabout$16millionto$17millionofnegativeimpactasitcomparestoprioryear.
BrooksWest (Analyst-PiperJaffray&Co.):
Okay.AndthenIguessonebigpictureforme,guys.Itlookslikenowyou'regoingtohavetheGoreroyaltythrough2019basedon,Iguess,thedecisionnottohearthecase.You'veexecutedwellagainsttheinvestmentplanyoulaidout.Reallytheonlythingyouhaven'tdoneisabigacquisition,soIguesstwo-partquestionforTim.
Howareyouthinkingaboutmitigatingthatfall-offintheGoreroyalty?Andcanyoujustupdateusonwhatyou'reseeingoutinthemarketandareyoustartingtogetmoreaggressive,givensomeofthedeclinesinmultipleswe'reseeing?Thanks.
T imothyRing (Chairman&CEO):
Sure.Ithinkit'salittleearlytocommentspecificallyon2019rightnow.Icantellyou,though,thatclearly,it'sveryvisibleinfrontofthis,it'sclearlya[noble]eventforusandwe'reobviouslyplanningorwhatwillbecomeovertime,obviously,we'vebeenplanningandanticipatingthat.
Sothat'sthecommentgenerallyabouttheGoreroyalties.Andrelativetoourbusinessdevelopmentactivity,weremainextremelyactive,goingthroughanumberofthingsinourwhatwecallfunnel,ifyouwill.AndIremainoptimisticthatthatlandscapecontinuestolookrobustforus.Andaswegoaheadandclosethings,we'llannouncethemwhentheyoccur.
CompanyName:CRBardIncCompanyTicker:BCRSector:HealthCareIndustry:HealthServices
EventDescription:Q32015EarningsCallMarketCapasofEventDate:14.07BPriceasofEventDate:178.44
©2014TheStreet,Inc.Al l R ightsReserved Page12of22
Operator :
And,Mr.West,didthatansweryourquestion?
BrooksWest (Analyst-PiperJaffray&Co.):
Yes,thankyou.
Operator :
Thanks.We'llmoveontoournextquestioninqueue.ThatwillcomefromDavidRomanwithGoldmanSachs.
DavidRoman (Analyst-GoldmanSachs):
Thankyou.Goodevening,everybody.IwantedustocomebacktoLutonixandgointotheutilizationinalittlebitmoredetail.Canyoutalktousabouthowyou'reseeingthisbeingusedinarealworldsetting?BecauseourunderstandingandfeedbackfromTCTisthatthisisatechnologythat'sgettingusedinabroadnumberofcases.Andit'snotsomuchprovingtobeareplacementforthingslikestenttherapyorathorectomy,it'sbeingmoreusedasanadjunct.
Canyoumaybegiveusyourperspectiveonthatandhowyou'reseeingtheadoptioncurverollout?
JohnDeFord (SVPScienceTechnologyandClinicalAffairs):
Yes,JohnDeFordhere.Letmetalkalittlebitabouttheutilization.IthinkwhatyouheardatTCTisfairlyconsistent.We'rebeginningtoseedrug-coatedballoonsusedassortofaninitialtherapy,notnecessarilythedestinationtherapy,butaninitialtherapy.Andthendependingontheoutcomeofthatinitialtherapy,makingotherdecisions.
Nowobviously,athorectomyorthingslikethatmightcomeintoplaypriortousinganykindofothertechnology,butbyandlargewe'reseeingdrug-coatedballoonsbeusedfirst,andthenasyouwouldexpect,ifthere'sprovisionalstentingrequired,thenstentsareused.Ifthereareothertechnologiesorotherpiecesneeded,thentheygetincluded.SoIdon'tthinkweeverexpectedDCBtoreplacesomeoftheseothertechnologies,butweareseeingitmoveexactlyasweexpected,tobethefirst-lineoftherapy.
Wethinkthere'sstillalongwaytogoasfarasgrowthandpenetration,butthisis--it'sstillearlydaysbutthat'swhatwe'reseeing.Ithinkthat'sfairlyconsistentwithwhatyou'veheard.
DavidRoman (Analyst-GoldmanSachs):
Okay.Andthenmaybejustabroaderquestion.Asyouthinkaboutthegrowthrate,2015hasobviouslyproventobeaverystrongperiodoforganicgrowthfortheCompany.AndIthinkwhenyoulaidouttheinvestmentplanearlieraboutinearly2013thisistheyearyouareenvisioninggrowingabovemarketgrowth.
Maybeyoucantalktousalittlebitaboutwhereweareintherealizationofthebenefitsfromthatinvestmentplanandtowhatextentyouthinkthetrendswe'veseenoverthepastninemonthsandwhatyou'reguidingforthefullyeararesustainable?
T imothyRing (Chairman&CEO):
Well,wehaven'tgivenguidancenorwillweonthiscallfor2016.Ithinkifyougobackandlookatwhat
CompanyName:CRBardIncCompanyTicker:BCRSector:HealthCareIndustry:HealthServices
EventDescription:Q32015EarningsCallMarketCapasofEventDate:14.07BPriceasofEventDate:178.44
©2014TheStreet,Inc.Al l R ightsReserved Page13of22
wesaidin2013isweexpectedtobeabovemarketrevenuegrowthoccurringaboutthispointintime.Andthenourexpectationbothwithnotonlytheinvestmentswemadethen,butwiththeinvestmentsongoing,isthatthatwouldbesustainable.Sothat'swhatwesaidafewyearsagoandthat'swhattheplanwas.Andwe'llgiveyouguidancefor2016inJanuary.
DavidRoman (Analyst-GoldmanSachs):
Maybeagainoneotherdifferentways.Ifyouthinkaboutthemomentuminthebusinessthatyou'reseeingtoday,isthereanypartyou'dascribetomacro-relatedfactors--Iknowthiscameupearlierinthecall--versusBard-relatedfactors?
T imothyRing (Chairman&CEO):
Youknow,onanygivenquarterandI--obviouslyIsaidearlierwewatchandlistentoeverybody.It'sverydifficultforanyCompany,Idon'tcarehowbigyouare,toknowifyou'vegainshare,lostshare,themarket'sincreasedorstayedflatordeclinedfromquartertoquarter.Iwouldn'tsayvirtuallyimpossibletoknowthatoverthatshortperiodoftime.Sowesaidinthepastitkindoffeltlikethingsweregettingalittlebitbetter.
Ithinkthatsomeoftheoldmetricsweusedtouselikehospitaladmissions,especiallywhenyou'reinvolvedinproceduresmaybearen'tthebell-weathersignsnecessarilytheywereafewyearsago.Sosomeofthedynamics,asyouknow,inhealthcareutilizationgenerallyarechanging.Soit'skindofdifficulttosay,whenyoulookathospitaladmissionmetricsmaybegoingdownandyetourrevenuecontinuestogrow,whatdoesallthatmean?
Justverydifficulttosay.Wesaidearlieratthelastcallitfeelsalittlebitbetter.Iwouldsaythatstillholdstrueforthisquarter.It'sjusthardtoputanyfinepointsonit.
ChristopherHolland (SVP&CFO):
TheonlythingI'dadd,Dave,andobviouslywetrackthesectorandwhenwelookatorganicgrowthratesacrossthesector,actuallythelastfourorfivequarters,theyare,frankly,prettyflatsequentially.Andobviously,wehavemovedhigheroverthatperiodoftime.
Soatleastthethingsthataregrowingforusinbothemergingmarketsandintheproductportfolio,andLutonixbeingpartofthat,arerelatedtothingswe'veinvestedinoverthelastcoupleofyears.Andsowehaven'tseenmaterialmoves[since]pointinvolumesorutilization.Andaswelookatthesector,itcertainlywouldappeartobethatimprovementinorganicgrowththatwe'veexperiencedisdirectlyrelatedtotheinvestmentsthatwemade.
DavidRoman (Analyst-GoldmanSachs):
Okay,great.Thankyouverymuch.
ChristopherHolland (SVP&CFO):
You'rewelcome.
Operator :
Thankyou.OurnextquestioncomesfromDavidLewiswithMorganStanley.
DavidLewis (Analyst-MorganStanley):
Goodafternoon.Chris,justaquickfollow-upontheJapanesedistributer.SotheEPSdilutionyouhad
CompanyName:CRBardIncCompanyTicker:BCRSector:HealthCareIndustry:HealthServices
EventDescription:Q32015EarningsCallMarketCapasofEventDate:14.07BPriceasofEventDate:178.44
©2014TheStreet,Inc.Al l R ightsReserved Page14of22
previouslydescribedobviouslyappearslikeit'sdroppingthroughandfullinthefourthquarter.Shouldweexpectthesametoholdtruein2016,thefull$0.20dropsstraightthroughorshouldweexpectittobeoffsetinsomeway?
ChristopherHolland (SVP&CFO):
Yes,Ithinkcertainlyit'sa$0.20whole,right,andit'spurelyrelatedtotheyen,justtobeclear.Soit'sawhole.Andobviouslywehaven'tgivenguidance,David,for2016.Butbecauseofthetransaction,we'refacingmuchmoresignificantyenheadwindsthanwewouldhavebeenotherwise.
Sowe'llobviously,aswerollupourbudgetanddecidewhatwe'rereadytocommittofor2016,wearestartingwithabigyenheadwindthatwewouldn'thavehad.Nowhavingsaidthat,it'saveryinterestingstrategicmoveforusandwebelieveitwillpaynicedividendslongtermfortheCompany,butit'saheadwindthatwe'lldealwithaswegointo2016.
DavidLewis (Analyst-MorganStanley):
Okay,andjustasafollow-up,maybequicklyforChris,canyougiveusasenseofwhatthataccretionorreturnlookslikein2017andbeyond?
AndjustforJohnDeFord,asitrelatestoLutonix,ifyougiveusasenseforinthefield,whatdoyouthinkisresonatingwithcliniciansmore,thetrialdataortheregistrydata?AndmoredirectlywhatI'mtryingtogetatis,wouldyouexpectanyimpactonyourbusinessbasedontheImpact1resultspostTCT?Thankyou.
ChristopherHolland (SVP&CFO):
Iwon'tbespecific,David,butassumingtheyenstaysroughlywhereitisandweexecute,whichincludessomeinterestingproductlaunchesforusintoJapanincludingLifeStentandLutonixovertimehere,thebusinessforuswillturnnicelyaccretivebeginningin2017andbeyond.ButI'mnotgoingtoputafinepointonitforyou.
JohnDeFord (SVPScienceTechnologyandClinicalAffairs):
Okay,andthenjustjumpingintotalkaboutthedata,wethinkthatcliniciansarereallyinterestedinlookingatbothpivotalandrandomizedstudiesandregistries.
IthinktheLevont2study,aspublishedinTheNewEnglandJournalofMedicineanditwasaveryuniquestudydesign.We'vealsofoundinthatstudythatprocedurereallymatters.Andthatwassomethingthatcameoutatpanel,cameoutinsomeofthepost-discussionsthatthewaythedevicewasusedcomparedtoPTAwasdifferent.
Andactuallyinourstudy,thedrug-coatedballoonwasused--whatyoucouldcallhadaless-effectivetreatmentattheendoftheprocedurecomparedtoPTA.Againthatisattributedtosomeoftheresultsthatweseeinourrandomizedstudy.
CertainlyIunderstandourcompetitorwantingtotrytoshiftthediscussionbacktotheirs.It'skindofinterestingtheyhaven'tupdatedtheirregistrydatayet,butourregistrydatarealworldisinmuchmoredifficultpatientsthanwesawinLevont2.Wethinkit'sreallydemonstratingtherealworldusageofthetechnology.
And,ofcourse,thoseclinicianswereeducatedonthethingsthatwe'velearnedintheLevont2studyontheimportanceoffullyinflatingtheballoons,gettinggoodexpansion,appropriateaccesstothevesselandthelesionquicklyandotherthingsthatwerediscussedbyDr.SchmidtatTCT.
CompanyName:CRBardIncCompanyTicker:BCRSector:HealthCareIndustry:HealthServices
EventDescription:Q32015EarningsCallMarketCapasofEventDate:14.07BPriceasofEventDate:178.44
©2014TheStreet,Inc.Al l R ightsReserved Page15of22
Andsowethinktheseresultsareprettyindicativeofrealworldusage,basedonthatnewknowledge.Nowwhatcliniciansaregoingtodo,sofarIthinkit'sresonatedprettywellthatdrug-coatedballoonswork,andatleastthetwotechnologiesonthemarkettodayseemtoworkprettysimilarly.
Operator :
Thankyouverymuch.Arewereadyforthenextquestion?
T imothyRing (Chairman&CEO):
Weare.
Operator :
Thanks.ItwillcomefromDavidTurkalywithJMPSecurities.
DavidT urkaly(Analyst-JMPSecurities):
Thanks.Didyouguysgivethepercentagethatemergingmarketswasinthequarter?
ChristopherHolland (SVP&CFO):
It'sabout9.5%oftotalsales,David.It'supabout120basispointsyear-over-year.Verystrongdouble-digitgrowthandobviouslycontinuingtomoveintherightdirectionoverall.Thereissomeseasonalitytothedifferentgeographies,butwehadanothergreatquarter.Andagainit'sactuallyacrossallofthegeographies,justlikewesawinQ2.
DavidT urkaly(Analyst-JMPSecurities):
Great.And,obviously,everyoneisawarethatyouhiredabunchoffolksthere.Iwasjustcurious,asyoulookattheirproductivity,whatwillthatlooklikeversussomeofyourUSorEuropeanrepsovertime?Andhowlongdoyouthinkittakessomeoftheseguystogetfullyrampedanduptospeed?
JohnWeiland (President&COO):
Well,Iwouldsaythatwe'redelightedwiththegroundgameofourteaminemergingmarkets.We'vebeenveryaggressiveintermsofaddingtothatfieldsalesforcearoundtheworldandaswe'vetalkedcontinually,thatsalesforcerepresentsabout34%ofourrepsaroundtheworld.
It'sthefastestareaofinvestmentsforusinfieldsalesreps,yetitonlyequalsalittlebitthanlessthan10%ofoursales,sowethinkwemadetherightinvestmentsforthelongterm.Weliketheuptickthatourpeoplearegivingusinthefieldastheygetseasoned.Takes,onaverage,ninemonthsto12monthsforapersontoreallybeproductivenomatterwhatgeographythatyou'reworkingin.AndIwouldsaythatwe'redelightedwiththeexecutionandthegroundgamethatourteamisputtingon,notonlyinemergingmarketsbutaroundtheworld.
DavidT urkaly(Analyst-JMPSecurities):
Great;thanksalot.
ChristopherHolland (SVP&CFO):
Sure.
Operator :
Thankyou.ThenextquestioninqueuewillcomefromKristenStewartwithDeutscheBank.
CompanyName:CRBardIncCompanyTicker:BCRSector:HealthCareIndustry:HealthServices
EventDescription:Q32015EarningsCallMarketCapasofEventDate:14.07BPriceasofEventDate:178.44
©2014TheStreet,Inc.Al l R ightsReserved Page16of22
KristenStewart (Analyst-DeutscheBank):
Hi,guys.
ChristopherHolland (SVP&CFO):
Hi,Kristen.
KristenStewart (Analyst-DeutscheBank):
Goodnight.Idon'tknowwhereJohnDeFordis,butIguessgoodafternoontoyou.
JohnDeFord (SVPScienceTechnologyandClinicalAffairs):
Itseemsdarkhere.Idon'tknowwhereyouare.
KristenStewart (Analyst-DeutscheBank):
Anyway,Iwasjustwonderingifyoucouldexpandalittlebitmore.IthinkyoumentionedtherewasdealerstockingwithFoleycathetersbecausethatseemedtobeupquitealot.Idon'trememberwhenbasicdrainagehasbeenuplike6%and7%intheUS.Sohowbigofastockingwasthereinquarterandwillthatjustpullfromthefourthquarteroristhat--wheredidthatshiftfrom?
ChristopherHolland (SVP&CFO):
Yes,andfrankly,Kristen,wedon'tknowforsureaswegetadditionaltracingdata.We'rejustspeculatingtherewassomeinthequarterandsowejustwantedtocautionyouagainstit.
ItcouldpossiblypullabitfromQ4andthatcertainlyisfactoredintoouroverallsalesguidance.SoIdon'twanttomaketoomuchofitandwecan'tsayforcertainyet.We'llknowmoreinthecomingweeksaswegetadditionaltracingdata.
JohnWeiland (President&COO):
I'dsayinthegrandschemeofthingsit'sareallysmallpointforusacross-the-board.
KristenStewart (Analyst-DeutscheBank):
AndthenIguessjustingeneral,justintermsof,Iguess,goingbackjusttotheM&Aside,Tim,isthereanythingintermsofthelandscapethatyou'reseeingthatmakesyoumoreorlesslikelytogooffintoanyadditionalareas,whetheritbepreferencetodomoresmallertuck-indealsforproductportfoliointheUSorareyouseeingorthinkingaboutdoingmoredealsthatmightgiveyougreaterexposureintointernationalmarketsatthispoint?
Ordoyoufeelcomfortablewiththeinvestmentsyoumadeinemergingmarkets,thatyouhavetherightinvestmentsthereandyou'recapableofgrowth,givenjusttheinvestmentsthatyouhavealready?
T imothyRing (Chairman&CEO):
Well,intermsofourlensesandourfilters,theanswerisyestoalloftheabove.We'relookingateverything.Sorelativetothelandscape,wekindoflikewhatweseeintermsofwhat'soutthere.Ourfiltersorourhurdleshavenotchangedrelativetoourpriorities.
Wedon'tstartwithsizeasoneofthefirstquestions.Infactprobablyit'sacoupleofreviewsthroughareadbeforeIevenstarttofocusonthat.Wefocusmoreonstrategicintent.
CompanyName:CRBardIncCompanyTicker:BCRSector:HealthCareIndustry:HealthServices
EventDescription:Q32015EarningsCallMarketCapasofEventDate:14.07BPriceasofEventDate:178.44
©2014TheStreet,Inc.Al l R ightsReserved Page17of22
Someoftheexamplesofthingswe'vedoneoverthelastcoupleofyears,targetedtemperaturemanagementisone,(inaudible)whatever,we'refocusedonrevenuegrowth,becausewethinkrevenuegrowthprovidesabettershareholderreturnthanslowerrevenuegrowththangrindingonearnings.Sowelookatrevenuegrowth,upside,sustainabilityofthat.
Weactuallylookateachinvestmentasisitaplatformtoinvestfurtherin,whetherthatbebothwithtechnology.Andclearly,atleastgiventhesizeofthetransactionswe'vedone,they'vehadlimitedcapabilitiesoutsidetheUnitedStatesjustfromtheexpenseandaffordabilitystandpoint,andwealreadyhavethatfootprint.Sowelookatallofthosethings.
ButI'moptimisticaboutwhatthelandscapelookslikeandwe'llseehowmanyofthoseactuallyclearourfilters,butwehaven'tchangedourstandardsatallinthelastseveralyears.
ChristopherHolland (SVP&CFO):
I'dadd,Kristen,obviouslywe'refocusedonfindinggoodtargetsinternationallyaswellthatfitallthesamecriteria.Andfrankly,withinemergingmarketswe'vecontinuedtostruggletofindgoodtargetsthatmeetthecriteriathatwehave.Andso,obviously,wenowhaveareallynicetrackrecordofexecutingorganicgrowth-drivenstrategiesalongthosemarkets,andsowe'llcontinuetodothatwhilewestilllook.Butwe'relooking,toTim'spoint,reallyaroundtheworldforopportunitiesthatarefirstandforemostproductleadershipopportunities.
KristenStewart (Analyst-DeutscheBank):
AndthebuyinginoftheJVoverinJapan,wasthatjustbecauseofthepressureofsellingindollarsandtheJVjusttakingahitwithcurrency?Orjustbenefitsofgoingdirect?
T imothyRing (Chairman&CEO):
Yes,maybealittlebackgroundhistoryherejustforthoseofyouthatmaynotknowthis.Soifyougobackintothe1990s,weactuallyhadalargeJapanlimitedbusinessandMedicon,thejointventurewithKobayashi,thatwasprimarilyresponsibleforoururologyproductline.
In1998wesoldoffthecardiologybusinessaspartofthattransaction,becauseoftaxdeals.ThatentityinJapanwentwiththattransaction,sowehadtomakeadecisionbackthen,doweputtherestofBard'sproductsintothejointventureordowestartourownbusinessthere?Backthenwemadethedecision,wehadalotofconfidenceandfaithinMedicon.Andobviouslythefactwejustboughtouttheotherhalf,wehaveevenmoresonow,movedtheentireproductlineintothatJV.
GiventhestructureoftheJV,aswe'veinvestedmoreheavilyinternallyinR&D,newproductlauncheswhichrequirealsoclinicaltrials,itjustputpressureonthebusinessmodelinJapan.Andstrategically,itmadeallofthesenseintheworldforustoownthethinginitsentiretysowecanmakealloftheinvestmentdecisionsweneedtomaketogrowthebusinessoverthelongterm.
KristenStewart (Analyst-DeutscheBank):
Thatmakessense.Okay,andlastone,justbecauseeveryotherhealthcarecompanyiscomingouttoday,doyouhaveanownershipstakeinanypharmacycompany?Sorry.
T imothyRing (Chairman&CEO):
Wedonot.
KristenStewart (Analyst-DeutscheBank):
CompanyName:CRBardIncCompanyTicker:BCRSector:HealthCareIndustry:HealthServices
EventDescription:Q32015EarningsCallMarketCapasofEventDate:14.07BPriceasofEventDate:178.44
©2014TheStreet,Inc.Al l R ightsReserved Page18of22
Sorry,Icouldn'tresist.(Multiplespeakers).It'sprobablynotfunnyforalotofpeoplewhohavedealtwithalotofstockstoday.But,anyway,haveagoodnight.
T imothyRing (Chairman&CEO):
Youtoo.
Operator :
Thankyou.OurnextquestioninqueuewillcomefromNeilChatterjiwithCowenandCompany.
NeilChatterji(Analyst-CowenandCompany):
Hi,thisisNeilonforJoshJennings.Thanksfortakingthequestion.Soyou'vehighlightedinthepasttargetedtemperaturemanagementandbiosurgerysegmentswithsignificantmarketopportunityexpansion.Thoseareseeingdouble-digitgrowth.Canyougiveusmorecoloronhowthoselinesaretrackingrelativetothatandwhenyoumightseesomesignificantramp?
JohnWeiland (President&COO):
Well,we'vebeenseeingsignificantrampinthoseproductlinessinceDayOneoftheacquisitions.We'vebeentakingshareannuallyinbothofthosemajorproductlinesthatweacquired.
We'vereallybuiltoutaverysuccessfulindependentsalesforce,prettylargebyUSstandardsinthatbusiness.AndIthinkthey'reexecutingextremelywell.Sowehavebeengrowingsubstantiallyinthatspace.Wewouldsuspectwe'llcontinuetoandwearealwayslookingforopportunitiestobeadjunctivetothoseproductlines.
ChristopherHolland (SVP&CFO):
OnlythingI'dadd,Neil,isbothofthoseopportunitiesplayoutoveranumberofyearsbecausethere'sanumberofadditionalindicationsthatourtechnologiesaregoingtobeaffectedwith,bothonthetargetedtemperaturemanagementsideaswellaswithinbiosurgery.
SotoTim'spointabouthavingacquiredplatformsthathaveaninvestmentopportunitybeyondtheinitialproductsetthatweacquired,we'vegotalongrunway,wethink,inbothofthosecategoriestogrowthemformanyyears.And,again,bothofthemaregrowingnicelyinthedoubledigitsaswesitheretoday.
NeilChatterji(Analyst-CowenandCompany):
Okay.Andjustonequickfollow-up.SoIbelieveyousawsomesoftnessinEuropeearlierintheyear,butthenvolumesseemedtorecoverinthesecondquarterandthenevenmoresointhethirdquarterhere.Howarethereimbursement[issues]shakingoutinEurope,particularlyinFrance?
JohnWeiland (President&COO):
Letmedealwiththemacroissuefirst.Ithinkthat'stheimportantone.AndthatisthatwedidhaveaslowfirstquarterandIthink,aswepredicted,wethoughttheyearwouldpickupanditcertainlyhas.Ourteamoverthereisexecutingextremelywell.
There'snothingfromamajorpricingstandpointgoingoninourbusinessinEurope.And,infact,ourEuropeteamwaspositiveinpriceforthequarter,sowedon'tseeabigissuerightnowloominginfrontofusintermsofreimbursementinFrance.
JohnDeFord (SVPScienceTechnologyandClinicalAffairs):
CompanyName:CRBardIncCompanyTicker:BCRSector:HealthCareIndustry:HealthServices
EventDescription:Q32015EarningsCallMarketCapasofEventDate:14.07BPriceasofEventDate:178.44
©2014TheStreet,Inc.Al l R ightsReserved Page19of22
TheonlyotherthingI'dadd,becauseIknowtherewassomecommentsmade,perhapsbyothersinthemarket,regardingspecificallyreimbursementfordrug-coatedballoonsinEurope,andIwouldjusttellyouthatisacategoryreimbursement,notkindofanindividualbrandreimbursement.We'reworkingveryhardtoexpandthataswellthroughoutEurope,so..
ChristopherHolland (SVP&CFO):
That'swhereTheNewEnglandJournalofMedicinepublication,frankly,helps.Havingthatkindofpublicationisrequiredincertaingeographiestohelpachievereimbursement.
NeilChatterji(Analyst-CowenandCompany):
Okay,thanks.
ChristopherHolland (SVP&CFO):
Thanks.Wehavecrossedthetopofthehour.We'regoingtotaketwomorequestionsandthenIapologizetoanyoneinthequeueafterthat.
Operator :
We'lltakethenextquestionfromMattTaylorwithBarclays.
MattT aylor (Analyst-BarclaysCapital):
Hi,thanksfortakingmyquestion.Ijusthadafollow-uponsomeoftheLutonixcommentary.Ijustwantedtoask,maybeinamorestraightforwardway,ifyoucouldjusttalkabouttheunderlyingtrendsandwhatyou'reseeingtheresequentiallyversusthestocking?Therewereafewstockingcomments.
Andthenconceptually,thepartnershipwithBostonScientifichasbeeninteresting.Curioustoknow,ifyoulookoutlongerterm,doyouthinktheyaregoingtobesellingameaningfulchunkofyouroverallLutonixsales?Ifyoucouldgiveusanysenseofwhatthesplitwouldbethere?Andthenisthereanyopportunitytoexpandthatpartnershipintootherproductareas?
ChristopherHolland (SVP&CFO):
SoIthinkjustthesequentialQ2,Q3,Q4.AndfirstthingI'dsayisweneedto,aswe'vesaid,itwillbenicetohavethisallsettleout,butit'sgoingtotakeafewquartersforthistosettleout.
SoBostonrampedupinQ2,certainlyhadsomestockinginQ2.AsIsaid,welaunchedacoupleofadditionalsizesinQ3,whichdrove,wethink,someadditionalstockinginQ3.Andsocertainly,wewouldexpectasequentialdeclineinQ4forBostonastheybegintoworkthroughthatinitialstockinginventory.
SowhenyouthenadjustforourbigstockingorderlastyearinQ4,we'reseeingreallyterrificbothsequentialandyear-over-yeargrowthinourbaseorganicLutonixbusinessandfeelreallygoodaboutourcompetitiveposition.AndJohnDeFordtalkedabouttherealworldregistrydatawhichis,frankly,outstanding.Sowe'llneedtogetthroughthesecoupleofquartershereandgettoasteadystatenextyearwhereBostonhasbeeninthebusinessnowwithusforawhileandwe'vebeenmovedbeyondourinitiallaunchintheUS.
T imothyRing (Chairman&CEO):
I'dsaytothelonger-termissueonBoston,wethinkthestrategywassoundthatweenteredinto.Your
CompanyName:CRBardIncCompanyTicker:BCRSector:HealthCareIndustry:HealthServices
EventDescription:Q32015EarningsCallMarketCapasofEventDate:14.07BPriceasofEventDate:178.44
©2014TheStreet,Inc.Al l R ightsReserved Page20of22
questionwaswillthey--whatkindofapositionwilltheyhavewithLutonix?Aswesetoutonthis,Bostonhadtherightstoselltheproductatasmallsubsetofcustomersandwerebasedonwheretheyhadgoodrelationshipsorapositioninacertaintherapythatwe'renotinvolvedin.
Wehavenoplanstoexpandthattootherproductlinestodayorcircumstances.IthinkthiswasauniqueopportunityforustobecomplementarywithBostoninasmallsegmentofcustomers,andIthinkthatwe'dlikethatposition,butBardwillberesponsibleforthegreatestmajorityofsalesinthegreatestmajorityofcustomersobviouslyaroundtheworld.
MattT aylor (Analyst-BarclaysCapital):
Okay,that'shelpful.Andtheonefollow-uponLutonix,Iguess.BroadlyjustfromthegooddatabothoutofyourregistryandtheMedtronicdatafromTCT.Doyouexpectthatoranyotherclinicalormarketexpansion[calous]tochangethegrowthrateintheneartermofthemarketordoyouthinkwe'rejustgoingtoseecontinuedgoodgrowth?
JohnDeFord (SVPScienceTechnologyandClinicalAffairs):
Well,I'lljumpinhere.Ithinkweexpectcontinuedgoodgrowth,butwealsothinkthatadditionalindicationsarereallyimportant.Sowetalkedaboutthestudies,theAVaccessstudybelowtheknee,in-stentrestenosis,otherindicationswethinkareadditionalcatalystforgrowth.Sowe'restrictlyandspecificallyfocusedonthoseareasandwe'llcontinuetobeso.
MattT aylor (Analyst-BarclaysCapital):
Great,thanksforthecolor.
ChristopherHolland (SVP&CFO):
You'rewelcome.
Operator :
Thankyou.OurnextquestionwillcomefromAnthonyPetronewithJefferies.
AnthonyPetrone (Analyst-JefferiesLLC):
Great,thanksfortakingthequestion.OneonLutonix,justwonderingifyoucanprovideanupdateonutilizationpercase,howmanyballoonsareactuallyusedpercase?Andthenoneisabroaderquestion.CommunityhealthreportedlowerrevenueperadmissiontodayandthatwasfromlowernegotiatedratesfromMedicare.
Andtheninadditionwe'reseeingconsolidationofprivatemanagedcarecompanies.I'mjustwonderinghowyouthinkthisplaysoutultimatelyinpriceformedicaldevicecompaniesovertime?Thanks.
JohnDeFord (SVPScienceTechnologyandClinicalAffairs):
I'mhappytojumpinontheLutonixside.IcantellyouthatI'mnotsurewehavespecificdatatoshareonnumberofdevisesusedpercase,justbecausewedon'treallyhaveinsightintothat.Unlesswehappentohavesomebodystandingintheroom,wewouldn'tnecessarilyknow.Icantellyoubythelesionlengthsthatwesee,wewouldexpecttosortofbeinthat1.3to1.5devisespotentiallypercasekindofaveragedout.
AnthonyPetrone (Analyst-JefferiesLLC):
That'shelpful.
CompanyName:CRBardIncCompanyTicker:BCRSector:HealthCareIndustry:HealthServices
EventDescription:Q32015EarningsCallMarketCapasofEventDate:14.07BPriceasofEventDate:178.44
©2014TheStreet,Inc.Al l R ightsReserved Page21of22
T imothyRing (Chairman&CEO):
Relativetothepricingscenarioandconsolidation,(inaudible)it'saverydynamicenvironmentgoingonrightnow.Pricingpressurehasalwaysbeenonusandothercompaniesinthespace.Ithinkspecificallyasyou--Ithinkthepricingdynamicistakingonalittlebitlargerormadealittlebitofalargerimpressionintheinvestmentcommunity,mainlybecauseofsomeofthebiotechandthepharmapricingissuesthathavebeeninthemediarecently.
Youknow,averylargepercentage--Ithinkit's50%ofourrevenuehasanASPoflessthan$500,probablycloserto$400.So75%ofourrevenueactually.Sowe'renotexactlyonthehighendoftheradarscreenherewhentheygettothat.
Nonetheless,theprocedures,theyareunderpressureandwhatwe'retryingtodoisdemonstratethevalueandthequalityandtheoutcomesanddoingthatwithdatawhichwe'regettingalotoftractionanduptakefromourcustomersastheymovemoretointheUSandHCOkindoforganizationstructure.
JohnWeiland (President&COO):
IthinkthatthosedatasetsarecertainlyveryhelpfulindrivingreimbursementandI'devidencethefullreimbursementforLutonixasaresultofthatvalueanalysisthatweworkedwithCMSon.
MattT aylor (Analyst-BarclaysCapital):
Thankyou.
ChristopherHolland (SVP&CFO):
You'rewelcome.
Operator :
Thankyou.And,ladiesandgentlemen,thisdoesconcludeourQ&Asession.I'dnowliketoturnthecallbackovertoBard'sManagementforclosingoradditionalcomments.
T imothyRing (Chairman&CEO):
Thankyouverymuch.
I'dliketothankallofyouforjoiningustoday,andalsoclosebythankingBardemployeesgloballyforitsstrongyearofexecutionsofar.Sowe'llupdateyouagainonourprogressinJanuary.Thanks,everybody.
Operator :
Thankyou.Ladiesandgentlemen,thatdoesconcludeourconferencecallfortoday.
Allrightsreserved(c)2014TheStreet,Inc.
Pleasefeelfreetoquoteupto200wordspertranscript.Anyquoteshouldbeaccompaniedby"ProvidedbyTheStreet"andalinktothecompletetranscriptandwww.thestreet.com.Anyotheruseormethodofdistributionisstrictlyprohibited.
THEINFORMATIONCONTAINEDINEACHWRITTENORAUDIOTRANSCRIPT(the"TRANSCRIPT")ISAREPRODUCTIONOFAPARTICULARCOMPANY'SCONFERENCECALL,CONFERENCEPRESENTATIONOROTHERAUDIOPRESENTATION.THETRANSCRIPTSAREPROVIDED"ASIS"AND"ASAVAILABLE"ANDTHESTREETISNOTRESPONSIBLEINANYWAYNORDOESITMAKEANYREPRESENTATIONORWARRANTYREGARDINGTHEACCURACYORCOMPLETENESSOFTHETRANSCRIPTSASPRODUCED,NORTHE
CompanyName:CRBardIncCompanyTicker:BCRSector:HealthCareIndustry:HealthServices
EventDescription:Q32015EarningsCallMarketCapasofEventDate:14.07BPriceasofEventDate:178.44
©2014TheStreet,Inc.Al l R ightsReserved Page22of22
SUBSTANCEOFAPARTICULARCOMPANY'SINFORMATION.
THETRANSCRIPTSAREPROVIDEDFORINFORMATIONALPURPOSESONLY.THESTREETISNOTPROVIDINGANYINVESTMENTADVICEORENDORSINGANYPARTICULARCOMPANY.